CHMP July 2026: 12 New Medicines Recommended
CHMP July 2026 meeting highlights show twelve new medicines recommended for EU approval, eight indication extensions, and three negative opinions. EMA published the 20–23 July plenary outcomes on 24 July 2026, spanning lipids, ophthalmology, dermatology, rare disease, antivirals and generics.
Contents10 sections
Key Takeaways
- Twelve new medicines received positive CHMP opinions; eight authorised products got indication extensions.
- Notable firsts: Susvimo ocular implant for nAMD; Icotyde as first oral IL-23 receptor psoriasis medicine.
- Lipid package includes Lyrokaul (lerodalcibep), Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe).
- Negative opinions: KemSu, Meplyffa and Qezzaqar; re-examinations requested for Yartemlea and Xervyteg after June negatives.
July 2026 CHMP outcomes at a glance
| Field | Detail |
|---|---|
| Meeting dates | 20–23 July 2026 |
| Highlights published | 24 July 2026 |
| New positive opinions | 12 medicines |
| Indication extensions | 8 (Enhertu, Jivi, Piqray, Repatha, Riltrava Aerosphere, Rinvoq, Trixeo Aerosphere, Trodelvy) |
| Negative opinions | 3 (KemSu, Meplyffa, Qezzaqar) |
| Re-examinations requested | Yartemlea (narsoplimab); Xervyteg (pooled faecal microbiota) |
What new medicines were recommended?
EMA said three lipid medicines were recommended for primary hypercholesterolaemia or mixed dyslipidaemia: monthly self-injectable Lyrokaul (lerodalcibep) and oral daily Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe). Susvimo (ranibizumab) won a positive opinion as a refillable ocular implant for stable wet AMD. Icotyde (icotrokinra) was recommended for moderate-to-severe plaque psoriasis from age 12.
Also positive: Lynavoy (linerixibat) for cholestatic pruritus in primary biliary cholangitis; Nezglyal (leriglitazone) under exceptional circumstances for cerebral adrenoleukodystrophy; Zokovea (ensitrelvir) for COVID-19 post-exposure prophylaxis; biosimilar Cavoley (pegfilgrastim); and generics Riociguat Accord, Ruxolitinib Viatris and Tafamidis Accord.
Primary source: EMA CHMP meeting highlights 20–23 July 2026.
Which indication extensions moved forward?
CHMP recommended extensions for Enhertu, Jivi, Piqray, Repatha, Riltrava Aerosphere, Rinvoq, Trixeo Aerosphere and Trodelvy. Exact new populations are detailed in the individual variation documents linked from the highlights page.
What were the negative opinions and re-examinations?
- KemSu (sufentanil/ketamine) for acute pain in children 1 to less than 18 years — negative
- Meplyffa (arimoclomol citrate) for Niemann-Pick type C — negative
- Qezzaqar (catequentinib) for synovial sarcoma or leiomyosarcoma — negative
- Applicants for Yartemlea and Xervyteg requested re-examination of June 2026 negative opinions
EMA publishes Q&A documents with each refusal. Committee process overview: EMA CHMP committee page.
Why does this meeting matter for European access?
Positive opinions now go to the European Commission for centralised marketing authorisations. Separate deep dives cover Susvimo, Icotyde and obicetrapib. Historical volume context: EMA's 2025 approval tally.
What remains uncertain?
Commission timing differs by product. Negative opinions may be re-examined or withdrawn. Exceptional-circumstances authorisations such as Nezglyal carry specific evidence obligations. National reimbursement will determine real patient access after any Commission decision.
Related NovaPharma coverage
Frequently Asked Questions
How many new medicines did CHMP recommend in July 2026?
EMA said the CHMP recommended twelve medicines for approval at its 20–23 July 2026 meeting, plus extensions of indication for eight already authorised medicines, and adopted negative opinions for three applications.
Which July 2026 recommendations were highlighted as firsts?
EMA highlighted Susvimo as the first refillable ocular implant of its kind recommended in the EU for wet AMD, and Icotyde (icotrokinra) as the first oral medicine targeting the interleukin-23 receptor for plaque psoriasis.
Which medicines received negative CHMP opinions in July 2026?
EMA listed negative opinions for KemSu (sufentanil/ketamine) for paediatric acute pain, Meplyffa (arimoclomol citrate) for Niemann-Pick disease type C, and Qezzaqar (catequentinib) for synovial sarcoma or leiomyosarcoma.
